Advanced Cell Technology Inc., of Alameda, Calif., expects to generate about $8.5 million as holders of its outstanding amortizing convertible debentures and common stock purchase warrants exercise their investment option to buy additional debentures and warrants. The company expects that financing to close on or about Sept. 7, 2006. In addition, Advanced Cell Technology agreed to reduce the exercise price of its outstanding $2.53 warrants and $1.27 warrants to 95 cents per share, provided that a minimum of 85 percent of holders of the $2.53 warrants exercise the warrants as repriced. The company will issue a replacement warrant to each holder at a price of $1.60. Funds from that transaction are expected to add another $5 million.

Biota Holdings Ltd., of Melbourne, Australia, said its partner, London-based GlaxoSmithKline plc, received approval from regulators in 15 European Union countries to extend the indications of Relenza (zanamivir for inhalation) for prevention of influenza in adults and children five years of age and above, and for treatment of flu in children five years of age and above. Relenza, an antiviral therapy, already is approved to treat flu in adults and adolescents 12 years and older.

Danisco A/S, of Copenhagen, Denmark, said it has withdrawn from the market the biofuel enzyme product that infringed Bagsvaerd, Denmark-based Novozymes A/S s Spezyme Ethyl patent, after a judge concluded that Novozymes infringement claims were valid and the patent is enforceable. The case is expected to proceed to trial in the fall to determine issues of willfulness and damages. Novozymes has claimed several million dollars in damages for lost profits. Danisco obtained the product through its acquisition of Genencor International Inc. in April 2005.

Diamyd Medical AB, of Stockholm, Sweden, said preliminary results of a Phase II trial of its lead drug candidate, Diamyd, demonstrated overall statistically significant efficacy in preserving insulin production in a Phase II trial in 70 children and adolescents with Type I diabetes. No adverse events associated with the therapy were observed. The company plans to evaluate its strategies on how to bring Diamyd to the market.